Tharimmune Inc is a biotechnology company developing a portfolio of therapeutic candidates for rare immune, inflammatory, and oncologic diseases... Show more
Get AI intraday signals
A.I. Advisor
published Earnings
THAR is expected to report earnings to fall 98.75% to -5 cents per share on November 29
Q3'23
Est.
$-0.05
Q2'23
Missed
by $3.84
Q1'23
Missed
by $5.52
The last earnings report on August 30 showed earnings per share of -400 cents, missing the estimate of -15 cents. With 16.98K shares outstanding, the current market capitalization sits at 2.49M.